Senti Biosciences Holdings, Inc. SNTI

SNTI Company Overview

Senti Biosciences Holdings, Inc. is a clinical-stage biotechnology company focused on developing engineered cell and gene therapies using synthetic biology. The company operates primarily in the biotechnology and immuno-oncology sectors, with a strategic emphasis on next-generation programmable medicines designed to improve precision, safety, and therapeutic durability. Its core technology platform centers on proprietary “Gene Circuit” engineering, which enables cells to sense and respond to biological signals in a controlled manner. The company’s primary revenue sources historically have included collaboration agreements, research partnerships, and financing activities, as it remains in the clinical development stage and has not yet established significant commercial product revenue.

Senti Biosciences was founded in 2016 and evolved from advances in synthetic biology and cellular engineering developed by researchers associated with leading academic and scientific institutions. The company became publicly traded through a merger with a special purpose acquisition company in 2022. Senti has positioned itself as a differentiated developer of logic-gated cell therapies, particularly in oncology applications where precision targeting may reduce toxicity associated with conventional CAR-NK and CAR-T therapies. Its lead programs have focused on allogeneic natural killer (NK) cell therapies engineered with synthetic gene circuits intended to selectively target cancer cells while sparing healthy tissue.